IRWD -  Ironwood Pharmaceuticals

-

$undefined

N/A

(N/A)

Ironwood Pharmaceuticals NasdaqGS:IRWD Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Location: 100 Summer Street, Boston, MA, 02110, United States | Website: https://ironwoodpharma.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

592.8M

Cash

108.5M

Avg Qtr Burn

N/A

Short % of Float

7.16%

Insider Ownership

2.53%

Institutional Own.

97.46%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Linzess® (linaclotide) Details
Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder

Approved

Quarterly sales

Approved

Quarterly sales

Apraglutide (agonist of the GLP-2 receptor) Details
Short bowel syndrome (SBS) with intestinal failure (IF)

Phase 3

Update

IW-3300 Details
Endometriosis, Visceral pain, Interstitial cystitis/bladder pain syndrome

Phase 2

Data readout

Apraglutide (agonist of the GLP-2 receptor) Details
Short bowel syndrome with colon-in-continuity , Short bowel syndrome

Phase 2

Update

Failed

Discontinued

CNP-104 Details
Primary biliary cholangitis, Liver disease, Autoimmune disease

Failed

Discontinued

Linaclotide Details
Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder, Constipation

Failed

Discontinued